AEROVANCE, INC

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing biotherapeutics. The company maintains a solid intellectual property position with its strong portfolio of potential breakthrough products now in clinical development and several pre-clinical programs. The lead products are human recombinant proteins: AEROVANT™, an IL-4 and IL-13 receptor antagonist currently in Phase 2a studies for asthma; AEROLYTIC™, a serine protease inhibitor in Phase 2a for Cystic Fibrosis; AERODERM™, an IL-4 and IL-13 receptor antagonist in Phase 2a for eczema, and PULMOLYTIC™, a serine protease inhibitor in Phase 2a for COPD.

Aerovance was spun off from Bayer Healthcare's biotechnology unit in August 2004 and has a proven executive team, experienced in the field of respiratory disease and biologics drug development. The company’s venture capital investors are Alta Partners, APAX Partners, Burrill & Company, Clarus Ventures, Lehman Brothers and NGN Capital.

Contact Details: 2929 7th StreetSuite 130 Berkeley California 94710 United States of America Tel: 510-549-5500 Fax: 510-549-5501 Email: info@aerovance.com WWW: www.aerovance.com/

Loading...

BioNews Results for AEROVANCE, INC:
Aerovance Completes Patient Enrollment in Phase 2b Clinical Trial of Aerovant? for Treatment of Uncontrolled A	Pharmacy Choice:  Nov 16 2009 4:32PM Matching: aerovance inc
Aerovance Completes Patient Enrollment In Phase 2b Clinical Trial Of Aerovant(TM) For Treatment Of Uncontrolled Asthma	Medical News Today:  Nov 5 2009 3:51AM Matching: aerovance inc
Aerovance Completes Patient Enrollment in Phase 2b Clinical Trial of Aerovant for Treatment of Uncontrolled As	Pharma Live:  Nov 5 2009 11:37AM Matching: aerovance inc
Medical News: Aerovance Completes Patient Enrollment In Phase 2b Clinical Trial Of Aerovant(TM) For Treatment Of Uncontrolled Asthma	Medical News Today:  Nov 4 2009 2:05PM Matching: aerovance inc
Medical News: Aerovance Completes Patient Enrollment In Phase 2b Clinical Trial Of Aerovant(TM) For Treatment Of Uncontrolled Asthma	Medical News Today:  Nov 4 2009 2:05PM Matching: aerovance inc
Promote your company here: BioNewsCast - Press Release Distribution	→View more AEROVANCE, INC news.

AEROVANCE, INC Clinical Trials:
A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)

AEROVANCE, INC Patents:
US Patent No.	Title
7452859	Human bikunin
7423123	Interleukin-9 antagonist muteins and their pharmacological methods of use
7404957	Modified IL-4 mutein receptor antagonists

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 581 times since April 2007, the link to the organisation's website has been followed 74 times

Recent Search Terms used to find this page: AER001 and patent | aerovance | number of employees at Aerovance | Aerovance | number of employees at aerovance in 2009 | aerovance mutein | .

Search for more companies in Berkeley

Search for more companies in California

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for AEROVANCE, INC